These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. A GLP-Compliant Toxicology and Biodistribution Study: Systemic Delivery of an rAAV9 Vector for the Treatment of Mucopolysaccharidosis IIIB. Meadows AS; Duncan FJ; Camboni M; Waligura K; Montgomery C; Zaraspe K; Naughton BJ; Bremer WG; Shilling C; Walker CM; Bolon B; Flanigan KM; McBride KL; McCarty DM; Fu H Hum Gene Ther Clin Dev; 2015 Dec; 26(4):228-42. PubMed ID: 26684447 [TBL] [Abstract][Full Text] [Related]
23. Restoration of central nervous system alpha-N-acetylglucosaminidase activity and therapeutic benefits in mucopolysaccharidosis IIIB mice by a single intracisternal recombinant adeno-associated viral type 2 vector delivery. Fu H; DiRosario J; Kang L; Muenzer J; McCarty DM J Gene Med; 2010 Jul; 12(7):624-33. PubMed ID: 20603889 [TBL] [Abstract][Full Text] [Related]
24. High and prolonged sulfamidase secretion by the liver of MPS-IIIA mice following hydrodynamic tail vein delivery of antibiotic-free pFAR4 plasmid vector. Quiviger M; Arfi A; Mansard D; Delacotte L; Pastor M; Scherman D; Marie C Gene Ther; 2014 Dec; 21(12):1001-7. PubMed ID: 25142140 [TBL] [Abstract][Full Text] [Related]
28. IgG-cleavage protein allows therapeutic AAV gene delivery in passively immunized MPS IIIA mice. Bobo TA; Samowitz PN; Robinson MI; Montes LI; Forsberg LJ; Feng R; Nicely NI; Fu H Gene Ther; 2023 Apr; 30(3-4):377-385. PubMed ID: 36253453 [TBL] [Abstract][Full Text] [Related]
29. Glycosaminoglycan levels and structure in a mucopolysaccharidosis IIIA mice and the effect of a highly secreted sulfamidase engineered to cross the blood-brain barrier. Maccari F; Sorrentino NC; Mantovani V; Galeotti F; Fraldi A; Volpi N Metab Brain Dis; 2017 Feb; 32(1):203-210. PubMed ID: 27585464 [TBL] [Abstract][Full Text] [Related]
30. Effect of cisternal sulfamidase delivery in MPS IIIA Huntaway dogs--a proof of principle study. Hemsley KM; Norman EJ; Crawley AC; Auclair D; King B; Fuller M; Lang DL; Dean CJ; Jolly RD; Hopwood JJ Mol Genet Metab; 2009 Dec; 98(4):383-92. PubMed ID: 19699666 [TBL] [Abstract][Full Text] [Related]
31. Impact of high-dose, chemically modified sulfamidase on pathology in a murine model of MPS IIIA. Rozaklis T; Beard H; Hassiotis S; Garcia AR; Tonini M; Luck A; Pan J; Lamsa JC; Hopwood JJ; Hemsley KM Exp Neurol; 2011 Jul; 230(1):123-30. PubMed ID: 21515264 [TBL] [Abstract][Full Text] [Related]
32. Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy. Haurigot V; Marcó S; Ribera A; Garcia M; Ruzo A; Villacampa P; Ayuso E; Añor S; Andaluz A; Pineda M; García-Fructuoso G; Molas M; Maggioni L; Muñoz S; Motas S; Ruberte J; Mingozzi F; Pumarola M; Bosch F J Clin Invest; 2013 Aug; 123(8):3254-3271. PubMed ID: 23863627 [TBL] [Abstract][Full Text] [Related]
33. Characterization of a C57BL/6 congenic mouse strain of mucopolysaccharidosis type IIIA. Crawley AC; Gliddon BL; Auclair D; Brodie SL; Hirte C; King BM; Fuller M; Hemsley KM; Hopwood JJ Brain Res; 2006 Aug; 1104(1):1-17. PubMed ID: 16828069 [TBL] [Abstract][Full Text] [Related]
35. Lentiviral-mediated gene correction of mucopolysaccharidosis type IIIA. Anson DS; McIntyre C; Thomas B; Koldej R; Ranieri E; Roberts A; Clements PR; Dunning K; Byers S Genet Vaccines Ther; 2007 Jan; 5():1. PubMed ID: 17227588 [TBL] [Abstract][Full Text] [Related]
36. Improvement in behaviour after substrate deprivation therapy with rhodamine B in a mouse model of MPS IIIA. Roberts AL; Rees MH; Klebe S; Fletcher JM; Byers S Mol Genet Metab; 2007; 92(1-2):115-21. PubMed ID: 17681480 [TBL] [Abstract][Full Text] [Related]
37. Delivery of an Adeno-Associated Virus Vector into Cerebrospinal Fluid Attenuates Central Nervous System Disease in Mucopolysaccharidosis Type II Mice. Hinderer C; Katz N; Louboutin JP; Bell P; Yu H; Nayal M; Kozarsky K; O'Brien WT; Goode T; Wilson JM Hum Gene Ther; 2016 Nov; 27(11):906-915. PubMed ID: 27510804 [TBL] [Abstract][Full Text] [Related]
38. Fluoxetine ameliorates mucopolysaccharidosis type IIIA. Capuozzo A; Montefusco S; Cacace V; Sofia M; Esposito A; Napolitano G; Nusco E; Polishchuk E; Pizzo MT; De Risi M; De Leonibus E; Sorrentino NC; Medina DL Mol Ther; 2022 Apr; 30(4):1432-1450. PubMed ID: 35121108 [TBL] [Abstract][Full Text] [Related]